Our Programme

A Richer Signal Class

Cirna reads what a tumour is actively doing

Protein markers infer that something is wrong. DNA reports what a tumour is. RNA reports what it is doing. The Cirna platform is built on the only analyte class that reads expressed transcripts — the broadest signal available in a blood draw — and reads SNPs, indels, splice and fusion variants, including the non-coding genome.

What the published work establishes

Three peer-reviewed studies have taken this from transcriptome-wide feasibility to a 36-variant panel that identified every HCC patient in its cohort. Specificity against the 35 cirrhosis controls is not reported; establishing it at a fixed operating point is the first objective of the validation programme ahead.

Panels are not cumulative across studies: the 2022 study reported 5,480 variants; the 2025 panel tested 288.

Patent position

PCT application WO 2025/117708, filed 27 November 2024 and published 5 June 2025, assigned to the Blumberg Institute. Inventors Block, Zezulinski and Sayeed. Pending; national-stage prosecution to follow. Hepion's rights arise under its licence from Cirna Diagnostics, LLC.

The path to market
01

Analytical validation — lock the variant panel; establish precision, limit of detection and reproducibility.

02

Clinical validation — prospective cohorts powered for early-stage sensitivity against cirrhotic controls.

03

CLIA launch — deploy as a laboratory-developed test.

04

Regulatory submission — pursue premarket authorisation on the accumulated evidence base.

No timeline or cost is asserted for any step. Clinical validation has not commenced, there is no clearance or approval, and the assay is not commercially available.